Latest News

You can find our latest news below

20 Dec, 2021

We wish you a wonderful holiday season and a happy new year 2022!

This year, we decided to donate our Christmas present funds to lonely elderly and gave a gift of companionship:

30 Nov, 2021

Our scientist has discovered new pairs for D-dimer immunoassay development for both chemiluminescence and lateral flow platforms.

30 Nov, 2021

We will be attending Medlab Middle East 2022 in the end of January.

01 Nov, 2021

Acute myocardial infarction (AMI) causes heart muscle damage and the release of troponin complex that can be detected in patients' blood by the measurement of its components. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT).

29 Oct, 2021

Procalcitonin (PCT) is the main marker of disorders that are accompanied by sepsis. The PCT levels in blood are elevated during the systemic inflammation. In addition, the concentration of PCT closely correlates with the severity of inflammation, which further supports the diagnostic value of the marker. While in normal conditions the amount of non-cleaved PCT in blood is low, it increases during systemic inflammation and sepsis.

05 Oct, 2021

We will be attending Medica 2021 in November.

05 Oct, 2021

The winner of the third EFLM-HyTest Cardiac Marker award will be announced by the EFLM President during the Opening Ceremony of the 24rd IFCC-EFLM European Congress - EuroMedLab in Munich.

23 Sep, 2021

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ), a leading global provider of medical devices and solutions, has completed its previously announced acquisition of HyTest Invest Oy and its subsidiaries (“HyTest”), a global leading provider of antibodies and antigens.

30 Aug, 2021

The loneliness of elderly people is a problem in Finland, the homecountry of HyTest. We wanted to be a part of the solution. That is why HyTest is now collaborating with a Finnish company called Gubbe.

16 Aug, 2021

We will be attending the 2021 AACC Annual Meeting & Clinical Lab Expo. The exhibition will be on August 26 - 30 in Atlanta.


07 Jul, 2021

Serum amyloid A is the only major acute phase protein in cats. It can be used as a sensitive marker of inflammation.

17 May, 2021

HyTest's current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. HyTest has been partnering with Mindray already for over ten years. In going forward, HyTest is committed to serving all of its customers and will continue to provide high-quality diagnostic raw materials as before.

28 Apr, 2021

Polyclonal SARS-CoV-2 NP antibodies provide an excellent addition to the mix of antibodies to select for COVID-19 Antigen test development.

27 Apr, 2021

Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

21 Apr, 2021

 By watching this webinar, you will learn about:
- inflammation process and its clinical importance
- the clinical value of Interleukin-6 and other inflammation markers, as well as the benefits and limitations of these markers for diagnostics
- the role of Interleukin-6 in distinguishing the severity and prognosis of COVID-19

31 Mar, 2021

We have now developed 7 new MAb pairs to IL-6 that are suitable for high sensitivity IL-6 assay development.

30 Mar, 2021

Angiotensin converting enzyme 2 (ACE2) and SARS-CoV-2 Nucleoprotein fragment N47-A173 samples available

29 Mar, 2021

Call for nominations! We are delighted to let you know that we are sponsoring the EFLM-HyTest Cardiac Marker Award for remarkable scientific work in the field of cardiovascular diseases.

24 Feb, 2021

Early diagnosis of acute myocardial infarction (AMI) as a life-threatening disorder is important for immediate evidence-based therapy. The cardiac troponin I (cTnI) is a gold standard and diagnostic cornerstone in the clinical assessment of AMI. It offers accurate and rapid AMI rule outs.

24 Feb, 2021

Meet HyTest China team at the 18th China Association of Clinical Laboratory Practice Expo held at Chongqing International Expo Center, on 28-30 March.

Do you need samples?

We are happy to make you an offer